Literature DB >> 27377157

Prostate cancer: Hypofractionated radiotherapy confirmed effective and safe.

Clemens Thoma.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27377157     DOI: 10.1038/nrurol.2016.129

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Authors:  Luca Incrocci; Ruud C Wortel; Wendimagegn Ghidey Alemayehu; Shafak Aluwini; Erik Schimmel; Stijn Krol; Peter-Paul van der Toorn; Hanja de Jager; Wilma Heemsbergen; Ben Heijmen; Floris Pos
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

2.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Authors:  David Dearnaley; Isabel Syndikus; Helen Mossop; Vincent Khoo; Alison Birtle; David Bloomfield; John Graham; Peter Kirkbride; John Logue; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Helen Patterson; Christopher Scrase; John Staffurth; Andrew Stockdale; Jean Tremlett; Margaret Bidmead; Helen Mayles; Olivia Naismith; Chris South; Annie Gao; Clare Cruickshank; Shama Hassan; Julia Pugh; Clare Griffin; Emma Hall
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.